Aktienanalyse zu Haemonetics Corp (HAE)HAEHaemonetics Corp

Haemonetics Corporation is a medical technology company. Its solutions address critical medical needs, which includes a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers, and products to enable blood centers to collect in-demand blood components. Its Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. Its Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies (Hemostasis Management, Cell Salvage and Transfusion Management products). It also offers solutions for structural heart and endovascular procedures. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Haemonetics Corp is a good buy right now due to its strong recent performance, with a 5.6% year-on-year revenue growth reported in Q2, and an adjusted EPS of $1.14, exceeding expectations by 5.8%. The current price of $103.96 is below the analyst price targets, which range from $100 to $119, suggesting significant upside potential. However, the recent net income drop to -20.15 million in Q4 poses a risk that investors should monitor closely.

9 analysts cover HAE: 3 rate it Buy, 5 Hold and 1 Sell. The average price target is 88.86.